Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)
Sponsor: James Graham Brown Cancer Center
Terminated
study terminated due to low accrual
Other terminated trials from James Graham Brown Cancer Center
Listed as NCT00673439, this PHASE2 trial focuses on Heparin-Induced Thrombocytopenia and remains terminated or withdrawn. Sponsored by James Graham Brown Cancer Center, it has been updated 11 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Dec 2019 [monthly]
Terminated PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- James Graham Brown Cancer Center
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .